MUNICH – September 10, 2019 – At the 2019 Beverage Packaging Conference in Munich, PolyOne today announced the commercial availability of ColorMat CLEVELAND – August 5, 2019 – PolyOne today announced availability of ColorMatrix™ Excelite™ IM chemical foaming additives (CFAs), formulated s

Avient Announces Asia Manufacturing and Availability of Cesa™ Non-PFAS Process Aid New Rutland™ Evolve™ Bio Plastisol™ Inks from Avient, containing 56-59% bio-derived content, are available from Rutland distributors beginning J

DATA C O M M U N I C AT I O N S C A B L E M A N U FA C T U R E R M I C R O C O A X C A B L E S • Achieve required level of deep black and opacity • Maintain a let down ratio (LDR) of approximately 5% • Ensure there are no clumps in the finished part • Conform to RoHS REACH compliance requirements • Delivered desired level of black and opacity to optimize conductivity • Provided LDR within the acceptable range, resulting in consistent processibility • Formulated a RoHS REACH compliant solution that helped lessen data interference by avoiding clumps in the finished part Colorant Chromatics™ PFA Jet Black KEY REQUIREMENTS WHY AVIENT? https://www.avient.com/products/polymer-colorants/fluoropolymer-color-concentrates/colorant-chromatics-pfa/mfa-concentrates

We began making our proxy materials available to shareholders on March 27, 2025. In preparing competitive market data for 2024, we drew from two independent sources. The second independent source of data that we used to augment the peer proxy analysis was the Consultant’s analysis of competitive market data relating to other applicable general industries.

Data Protection. Data Processing. These Terms are available at https://www.avient.com/company/policies-and- governance/avient-corporation-privacy-statement.

The replay will be available for one week beginning at the time required to consummate the acquisition of Clariant's color and additive masterbatch business; the satisfaction or waiver of conditions in the purchase agreements; any material adverse changes in Clariant's color and additive masterbatch business; the ability to obtain required regulatory or other third-party approvals and consents and otherwise consummate the proposed acquisition of Clariant's color and additive masterbatch business; our ability to achieve the strategic and other objectives relating to the proposed acquisition of Clariant's color and additive masterbatch business, including any expected synergies; our ability to successfully integrate Clariant's color and additive masterbatch business and achieve the expected results of the acquisition of Clariant's color and additive masterbatch business, including, without limitation, the acquisition being accretive; disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; the effect on foreign operations of currency fluctuations, tariffs and other political, economic and regulatory risks; changes in polymer consumption growth rates and laws and regulations regarding plastics in jurisdictions where we conduct business; changes in global industry capacity or in the rate at which anticipated changes in industry capacity come online; fluctuations in raw material prices, quality and supply, and in energy prices and supply; production outages or material costs associated with scheduled or unscheduled maintenance programs; unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; an inability to raise or sustain prices for products or services; an ability to achieve or delays in achieving or achievement of less than the anticipated financial benefit from initiatives related to acquisitions and integration, working capital reductions, costs reductions and employee productivity goals; information systems failures and cyberattacks; and other factors affecting our business beyond our control, including, without limitation, changes in the general economy, changes in interest rates and changes in the rate of inflation. The Company does not provide reconciliations of forward-looking non-GAAP financial measures, such as outlook for adjusted earnings per share, to the most comparable GAAP financial measures on a forward-looking basis because the Company is unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort.

Mevopur™ Healthcare Bio-based Polymer Solutions: color and additive concentrates based on polymers with 70-95% bio-content and pre-tested raw materials to help reduce carbon footprint and mitigate risk, available in pre-colored formulations, offer a sustainable drop-in replacement for fossil-based grades and can be processed and recycled in the same channels.  Customized colors and solutions are also available to meet specific needs. PCF values are available for these products and are based upon a TUV-certified ISO-14067: 2018 process.

The Company does not provide reconciliations of forward-looking non-GAAP financial measures, such as outlook for adjusted EBITDA, adjusted earnings per share, adjusted operating income and free cash flow, to the most comparable GAAP financial measures on a forward-looking basis because the Company is unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. D is t. ) K W R R P M P P G A V Y F U L G C P IF F H X L F M C F O E H U N E C L K R A E M N A S H C E S C L G R A A L B Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of April 27, 2021 Avient reflects 2021 estimated revenue of $4,300M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 84% Median: 77% H I G H F R E E C A S H F L OW C O N V E R S I O N Avient reflects 2021 estimated EBITDA of $560M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of April 27, 2021 87 89 87 86 82 81 76 88 87 84 82 81 78 77 77 77 76 73 70 69 50 19 A vi e n t K W R P P G R P M A V Y F U L G C P F M C IF F H X L U N V R E C L A S H C E B N R F O E E M N G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of April 27, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below specialty formulator peers and the majority of our chemical peers.

Find Data Find material data Flammability (1.5 mm) (non-PFAS* options available)

Board of Directors approves a 5 million increase in the number of shares available for share repurchase Board of Directors approved an increase of 5 million shares available for repurchases, bringing the company's total authorization to approximately 6 million shares. Reconciliation of Non-GAAP Financial Measures (Unaudited)(Dollars in millions, except per share data)